Column

Editor's Page

Biomarker Testing and Prospective Tracking Tools

10/18/2019

Winston Wong, PharmD, Editor-in-Chief

Even though researchers are making progress every day, the precision medicine approach to cancer treatment is not yet part of routine care. Another strategy that can contribute to more personalized medicine is the...

Even...

10/18/2019

Journal of Clinical Pathways

Editorial

Potential or Unnecessary Burdens and Challenges for Practices Under Proposed CMS Radiation Oncology Model

10/18/2019

Nicolas Ferreyros, Managing Director, Community Oncology Alliance

In July 2019, the Centers for Medicare & Medicaid Services (CMS) proposed a mandatory Radiation Oncology (RO) Model that would require participation to test whether prospective site neutral, episode-based...

In...

10/18/2019

Journal of Clinical Pathways

Business of Pathways

Broadening the Value Assessment Paradigm: Including the Value of Hope and the Value of Insurance

10/18/2019

Sean McElligott, MS

Ira Klein, MD, MBA, FACP—Column Editor

*/ /*-->*/ While social media is all about sharing, very little personal preference data makes its way into health plan contracting around specific interventions and pathway programs today. As a result, the...

...

10/18/2019

Journal of Clinical Pathways

Editor's Page

Learning From Pathways Experiences in the Field and Looking in Future Directions

09/20/2019

Winston Wong, PharmD, Editor-in-Chief

*/ /*-->*/ The guidance that comes from clinical pathways encourages widespread and consistent evidence-based practice of medicine by incorporating the most up-to-date clinical guidelines with efficacy and,...

...

09/20/2019

Journal of Clinical Pathways

Editorial

Including Financial Assistance in ASP a Dangerous Proposal for Patients With Cancer

09/20/2019

Ted Okon, Executive Director, Community Oncology Alliance

*/ /*-->*/ Just before the August 2019 recess, the Senate Finance Committee released its proposed Prescription Drug Pricing Reduction Act (drug package).1 There are provisions in the package that community...

...

09/20/2019

Journal of Clinical Pathways

Editorial

Featured Sessions at the Upcoming ACCC National Oncology Conference

09/20/2019

JCP Editors

Oncology stakeholders across disciplines and settings of care will come together in Orlando, FL, from October 30-November 1, 2019, for the Association of Community Cancer Centers (ACCC) 36th National Oncology...

...

09/20/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Federal Enforcement of Clinical Pathways, Resource Utilization Management

09/20/2019

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Providers order unnecessary tests for a variety of reasons: pressure from patients, fears of malpractice suit, not being knowledgeable about current “best” practices as well as for potential financial advantage for...

...

09/20/2019

Journal of Clinical Pathways

Editor's Page

Where We Are With Value Assessment in Oncology

08/19/2019

Winston Wong, PharmD, Editor-in-Chief

Value assessment in oncology is an emerging area of interest, as demonstrated by the multiple value assessment tools launched in the last 5 years to help stakeholders analyze the efficacy, tolerability, and...

Value...

08/19/2019

Journal of Clinical Pathways

Editorial

Strategic Vision of the OCM 2.0 Alternative Payment Model

08/19/2019

JCP Editors

In June 2019, the Community Oncology Alliance (COA) announced a detailed alternative payment model (APM) that includes proposals for value-based contracts that would provide high-quality oncology care at a low cost....

In...

08/19/2019

Journal of Clinical Pathways

PATIENT PERSPECTIVE

Can We Talk? Discussing What Matters With the People Who Matter

08/19/2019

Melissa Williams, MPH

Rebecca Kirch, JD

Alan Balch, PhD—Column Editor

Literature shows that patients feel better when they have the opportunity to express emotional concerns and their physicians respond empathically. When patients feel heard and understood, they are also better...

...

08/19/2019

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Column

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products